(Q36284075)

13 August 2017

1 reference

title

Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure (English)

1 reference

acute decompensated heart failure

13 August 2017

0 references

1 reference

Grace L Earl

1

1 reference

13 August 2017

James T Fitzpatrick

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

11 October 2005

1 reference

Annals of Pharmacotherapy

13 August 2017

published in

1 reference

13 August 2017

volume

39

1 reference

13 August 2017

issue

11

1 reference

13 August 2017

page(s)

1888-1896

1 reference

Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial

13 August 2017

cites work

1 reference

Inotropic therapy for heart failure: an evidence-based approach.

21 January 2018

1 reference

Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

21 January 2018

1 reference

Levosimendan: Implications for Clinicians

21 January 2018

1 reference

Beneficial effects of the Ca(2+) sensitizer levosimendan in human myocardium

21 January 2018

1 reference

Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium

21 January 2018

1 reference

Levosimendan improves diastolic and systolic function in failing human myocardium.

21 January 2018

1 reference

Levosimendan, a new calcium-sensitizing inotrope for heart failure

21 January 2018

1 reference

The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan

21 January 2018

1 reference

Levosimendan increases L-type Ca(2+) current via phosphodiesterase-3 inhibition in human cardiac myocytes

21 January 2018

1 reference

Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes.

21 January 2018

1 reference

Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake

21 January 2018

1 reference

Myocardial efficiency during levosimendan infusion in congestive heart failure.

21 January 2018

1 reference

Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology

21 January 2018

1 reference

Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management

21 January 2018

1 reference

Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.

21 January 2018

1 reference

Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients

21 January 2018

1 reference

The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine

21 January 2018

1 reference

Population pharmacokinetics of levosimendan in patients with congestive heart failure

21 January 2018

1 reference

Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan

21 January 2018

1 reference

Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure

21 January 2018

1 reference

Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators

21 January 2018

1 reference

Development of level A, B and C in vitro-in vivo correlations for modified-release levosimendan capsules

21 January 2018

1 reference

Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study

21 January 2018

1 reference

Transdermal delivery of levosimendan

21 January 2018

1 reference

Sustained hemodynamic effects of intravenous levosimendan

21 January 2018

1 reference

Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

21 January 2018

1 reference

Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).

21 January 2018

1 reference

The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies

21 January 2018

1 reference

The contractility enhancing effect of the calcium sensitiser levosimendan is not attenuated by carvedilol in healthy subjects

21 January 2018

1 reference

Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure

21 January 2018

1 reference

Myocardial efficiency during calcium sensitization with levosimendan: A noninvasive study with positron emission tomography and echocardiography in healthy volunteers*

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1G128

1 reference

13 August 2017

1 reference